Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study.

Shijia ZhangKimberly TangGuihong WanNga NguyenChenyue LuPearl Ugwu-DikeNeel RavalJayhyun SeoNora A AlexanderRuple JairathJordan PhillippsBonnie W LeungKathleen RosterWenxin ChenLeyre ZubiriGenevieve BolandSteven T ChenHensin TsaoShadmehr DemehriNicole R LeBoeufKerry L ReynoldsKun-Hsing YuAlexander GusevShawn G KwatraYevgeniy R Semenov

Published in: medRxiv : the preprint server for health sciences (2023)

Patients on immune checkpoint inhibitors (ICIs) who developed cutaneous immune-related adverse events (cirAEs) had favorable outcomes. This was especially notable for melanoma patients who had cirAEs, both those with vitiligo and other morphologies.Development of cirAEs in ICI-treated patients can be used to prognosticate survival and guide treatment decisions.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
type diabetes
metabolic syndrome
adipose tissue
insulin resistance